Basal follicle stimulating hormone (FSH) in a natural cycle, FSH on cycle days 3 and 10 in a domiphene citratestimulated cycle and oestradiol and progesterone area under the curve (AUC) in the luteal phase of the domiphene citrate-stimulated cycle were evaluated as hormonal predictors for the outcome of FVF treatment in 53 normally cycling women with tubal infertility. The pregnant women had significantly fewer treatment cycles (P < 0.001) and needed fewer ampoules of gonadotrophins (P < 0.001). They also had more oocyte retrievals (P < 0.001), more oocytes per retrieval (P < 0.01), higher fertilization rate (P < 0.001) and more replaced pre-embryos per replacement (P < 0.01) as compared with non-pregnant women. Significant differences were found in FSH concentrations on cycle days 3 (P < 0.05) and 10 (P < 0.001) after domiphene citrate stimulation and for oestradiol and progesterone AUC in the luteal phase (P < 0.001) between those women who became pregnant and those who did not become pregnant after IVF treatment Luteal oestradiol and progesterone had considerably stronger predictive value for the outcome of IVF treatment as compared to basal FSH and domiphene citrate challenge test
Introduction
In-vitro fertilization (IVF) has become an efficient primary infertility treatment method. The indications have successively widened and the results have improved. Nevertheless, most IVF treatment cycles do not result in pregnancy although by repeating the procedure, a take-home baby rate of >50% can be achieved within one to three cycles (Bergh et al, 1995) . The number of unsuccessful IVF treatments could probably be reduced if strong predictive factors were available to improve patient counselling when choosing between IVF (with the couple's own gametes) and alternative methods.
For outcome prediction, the age-related impediments to conception have been considered in infertility treatment, including IVF (Meldrum, 1993) . However, recently more accurate predictors of impaired ovarian function have been 2396 identified. Much evidence has accumulated supporting raised basal follicle stimulating hormone (FSH) level as a predictor of poor IVF outcome (Scott et al, 1989; Ahmed Ebbiary et al, 1994) . The prognostic value of this marker is further improved by the use of the domiphene citrate challenge test (Navot et al, 1987; Loumaye et al, 1990; Tanbo et al, 1992; Scott et al, 1993) . Thus, a follicular phase hormonal marker of the natural or domiphene citrate-stimulated cycle can predict the outcome of IVF treatment based on gonadotrophin stimulation and luteal support. So far there is little information about the prognostic value of hormonal markers of the luteal phase. Therefore, the present study was designed to evaluate oestradiol and progesterone levels during the luteal phase and compare them to basal follicle stimulating hormone (FSH) and domiphene citrate test as predictors for IVF treatment outcome in regularly menstruating women with tubal infertility.
Materials and methods
A total of 53 women (age 27-38 years) on the waiting list for IVF treatment, who had failed to conceive at least 2 years following tubal reconstructive surgery, was included in the study. All women were regularly menstruating and underwent, prior to surgery, a complete investigation for infertility, including basal body temperature, characterization of the menstrual cycle by serum concentrations of luteinizing hormone (LH), FSH, oestradiol in the early follicular phase and progesterone 6-7 days after ovulation. All fulfilled our standard criteria for normal ovulatory cycles (Landgren et al, 1980) . All males had normal spermiograms on at least two occasions according to the World Health Organization (WHO, 1987) criteria. Before the couples underwent their first IVF cycle monitoring was carried out as outlined below.
Study plan and cycle monitoring
All women participating in the study were investigated during two complete screening cycles. The first was a randomly selected natural cycle. In the second cycle clomiphene citrate challenge test was performed by administration of 100 mg clomiphene citrate (Pergoume, Serono Nordic AB, Stockholm, Sweden) on cycle days 5-9 (Navot et al, 1987) . Each subject was monitored by vaginal ultrasound using a real-time scanner Sonoline SI/200 (Sonoline SI/200, SiemensEdema AB, Sundoyberg, Sweden), equipped with mechanical sector rotating 5-7.5 MHz transducer. For determination of the LH peak, morning urine and blood samples were collected from cycle day 10 to LH+2, using a self-test (OvuQvick; Monoclonal Antibodies Inc. Sunnyvale, CA, USA). Peripheral blood samples were collected by venepuncture in the morning between 0730 h and 0830 h on days 3 and 10 of the menstrual cycle measuring FSH, and for LH at the time of ovulation (days 10-15) and for 4 days (LH+3-LH+9) to assess oestradiol and progesterone. Blood was separated by centrifugarion within 1 h and the serum stored at -20°C until assayed
Hormonal measurement
Circulating concentrations of LH, FSH, oestradiol and progesterone were measured by radioimmunoassay using commercial kits (Diagnostic Products Corporation, Los Angeles, CA, USA). The interassay and mtra-assay coefficients of variation were 7.2 and 6 8% for LH, 5.7 and 4.3% for FSH respecuvely Oestradiol and progesterone assays had interassay and intra-assay coefficients of variation 7.6 and 7.2%, and 4.7 and 5.2% respectively.
In the luteal phase progesterone and oestradiol concentrations were expressed as the areas undeT the curve (AUC), which were calculated as sums of partial areas obtained according to the following formula
where t is tune in days and a, b, c and d are successive levels of progesterone and oestradiol on days LH + 3, LH + 5, LH + 7 and LH + 9 respectively.
IVF treatment
All patients followed our standard ovarian stimulation protocol as described recently (Csemiczky et al., 1994) . After 14-20 days of gonadotrophin releasing hormone agonist (Suprefact, Svenska Hoechst AB, Stockholm, Sweden) nasal spray treatment ovanan sUmulation was started by i.m. injection of human menopausal gonadotrophin (HMG) or pure FSH (Pergonal, Fertinorm HP, Serono Nordic AB) 150-225 IU daily. Follicular development was monitored by vaginal ultrasonography and measuring serum oestradiol concentrations. The day for ovum retrieval was determined when the leading follicle reached a diameter of 17 mm and the serum levels of oestradiol reached at least 2500 pmol/1 Then 5000 IU human chononic gonadotrophin (HCG; Profasi Serono Nordic AB) was given, and follicle aspiration was performed 35-36 h later by the vaginal ultrasound-guided technique. Gamete and pre-embryo handling as well as embryo replacement have been described elsewhere (SundstrOm and Wramsby, 1989) . Spermatozoa were prepared by the swim-up technique. Luteal phase support was given using 5000 IU HCG i.m. at 3, 6 and 9 days after embryo replacement During the study period, treatment was restricted to three cycles and the number of replaced pre-embryos was limited to three. Pregnancy was defined as a significant increase in serum HCG concentrations in at least two measurements not earlier than 14 days after the embryo replacement and repeated 2 days later. Ultrasound examination was performed 5 weeks from embryo replacement for localization of pregnancy and at 9-12 weeks gestauonal age in order to confirm fetal viability
Statistics
Results are presented as means ± SD. Statistical evaluation was performed using Student's r-test and Fisher's exact test whenever appropriate.
Comparisons of the hormonal characteristics between the groups were performed by using the Mann-Whitney two-tailed test. The prognostic value of the hormonal parameters was determined by identifying the proportion of women who became pregnant, and those who did not become pregnant Cut-off values were chosen according to pregnancy outcome. FSH concentrations on cycle days 3 and 10 were below the cut-off value of 7 IU/1 in those women who became pregnant Corresponding esumations were performed regarding progesterone and oestradiol AUC during the luteal phase.
A probability <0.05 was considered to be statistically significant
Ethical aspects
The protocol of mis study was approved by the Local Ethics Committee of the Karolinska Hospital
Results
Clinical characteristics with respect to outcome of IVF treatment are shown in Table I . Age, height, weight, body mass index (BMT), cycle, follicular and luteal phase length, and follicular phase:luteal phase ratio did not differ between those who became pregnant and those who did not. The pregnant women had significantly fewer treatment cycles (P < 0.001) and needed fewer ampoules of gonadotrophins (P < 0.001). They also had more oocyte retrievals per started cycle (P < 0.001), more oocytes per retrieval (P < 0.01), higher fertilization rate (P < 0.001) and more replaced pre-embryos per replacement (P < 0.01) as compared with non-pregnant women. When the hormonal parameters were analysed, FSH concentrations on cycle day 3 in the non-pregnant women were elevated as compared to the pregnant women (P < 0.05) in the natural as well as in the clomiphene citrate-stimulated cycles (Table II) .
Highly significant differences between pregnant and nonpregnant women were found in FSH concentrations on cycle day 10 of clomiphene citrate-stimulated cycles (P < 0.001) and for oestradiol and progesterone AUC in the luteal phase both in the natural and clomiphene citrate-stimulated cycle (P < 0.001).
The sensitivity and positive predictive value for pregnancy outcome of FSH on cycle days 3 and 10, progesterone and oestradiol AUC during the luteal phase in the clomiphene citrate cycles are shown in Table in . Cut-off values were chosen with respect to positive treatment outcome (pregnancy) for each predictor. Out of these parameters, oestradiol AUC was found to be the most sensitive and to have the highest positive predictive value.
Discussion
It has been clearly shown that subtle endocrine abnormalities in regularly menstruating women may be revealed after hormonal monitoring (Polan et al., 1982; GeisthSvel et al, 1983) or by clomiphene citrate challenge test (Navot et al, 1987) . Basal FSH on cycle day 3 has been proposed as a better indicator of impaired ovarian reserve (Toner et al., 1991; Scott and Hofmann, 1995) than other parameters such as age and menstrual history. Accordingly, the present study demonstrated that normally menstruating women with tubal infertility exhibited quite different hormonal characteristics in pre-treatment screening cycles. Moreover, these endocrine markers could be used as predictors for the outcome of IVF treatment. In the follicular phase, basal FSH and clomiphene citrate challenge test and in the luteal phase progesterone and oestradiol AUC differed significantly between those women who became pregnant and those who did not after IVF treatment. When the predictive value was calculated for these four hormonal indicators, the positive predictive value was highest for oestradiol AUC during the luteal phase.
When LH, FSH, oestradiol and progesterone profiles in a group of women with unexplained infertility were compared with normal controls (Lenton et al., 1978) , progesterone concentrations were significantly lower in the infertile women. (93) 118 (2 8) 22 (52) 0 22 14 (64) volunteers undergoing in-vitro Not pregnant 31 33 7 ± 2.0 167 ± 7 2 63.5 ± 7 7 22.4 ± 3.0 29 1 ± 2.8 14 8 ± 48 15.6 ± 1.9 0.9 ± 0.2 93 (3.0) 314 + 39
74 (80) •Cycle days 3 and 10 FSH » 7 IU/1, progesterone AUC s» 470 nmol/lxdays, oestradiol AUC » 6900 pmol/lxdays.
•"Cycle days 3 and 10 FSH < 7 IU/1, progesterone AUC >470 nmol/lxdays, oestradiol AUC > 6900 pmol/lxdays c Calculated as proportion of non-pregnant women with abnormal test result.
•"Calculated as proportion of women with normal test result who become pregnanL Therapy with progesterone supplementation of the luteal phase or stimulation by either anti-oestrogen or gonadotrophins did not result in pregnancies, although progesterone concentrations were increased. In another study by Ahmed Ebbiary et al.
(1994) infertile women with high basal FSH concentrations did present with slower follicular growth, smaller follicular diameter and lower luteal progesterone as compared to infertile women with normal FSH. These results are in agreement with the findings in the present study, indicating premature ovarian failure, representing a stage of mcnopausal transition in infertile women, with high basal FSH concentration, displayed as poor follicular growth, few oocytes and poor pregnancy outcome during three subsequent IVF cycles. The prognostic value of oestradiol and progesterone during the luteal phase for IVF treatment outcome was higher than FSH in the follicular phase.
Since the number of women in this study was relatively small, there is a need for larger prospective evaluation of the prognostic reliability of these parameters for IVF treatment outcome. Larger series will be required to determine with confidence within-patient variation of each of the tests, as well as the various cut-off points. Concerning basal FSH, equivalent results on cycle days 2-5 and no significant cycle to cycle variability have been reported (Hansen et aL, 1996) .
In conclusion, a number of hormonal parameters in the follicular and luteal phases were identified to be of value for prediction of the IVF treatment outcome. Luteal oestradiol and progesterone AUC had stronger predictive value as compared with basal FSH and clomiphene citrate-challenge test Before using these markers in patient counselling they should be further evaluated in prospective studies. Scott, R.T. Jr, Leonardi, M R., Hofmann, OB et aL ("1993 Received on May 13, 1996 , accepted on September 25, 1996 
